Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice

Toxicology and Applied Pharmacology

Volumn 263, Issue 2, 2012, Pages 131-137

  Park, Young Joo ^a,b   Lee, Eun Kyung ^a,d   Lee, Yoon Kwang ^c,e   Park, Do Joon ^a   Jang, Hak Chul ^a   Moore, David D ^c  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d National Cancer Center   (South Korea)

^e Northeastern Ohio Medical University   (United States)

Author keywords

Cytochrome P450; Thyroid hormone; Xenobiotic receptor

Indexed keywords

CARBAMAZEPINE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B10; CYTOCHROME P450 3A11; IODINE; MESSENGER RNA; PREGNANE X RECEPTOR; PROPYLTHIOURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOTHYROIDISM; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; WILD TYPE;

ANIMALS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CARBAMAZEPINE; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; HYPOTHYROIDISM; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; STEROID HYDROXYLASES; SURVIVAL RATE;

MUS;

EID: 84865068640     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.03.017     Document Type: Article

References (39)

1. Badger D., Kraner J., Fraser D., Hoglen N., Halpert J., Sipes I.G. Reduction of thyroid hormone may participate in the modulation of cytochromes P450 2C11 and 3A2 by retinol. Life Sci. 1998, 63:PL367-PL372.
2. Brtko J., Dvorak Z. Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes. Curr. Drug Metab. 2011, 12:71-88.
3. Chu V., Einolf H.J., Evers R., Kumar G., Moore D., Ripp S., Silva J., Sinha V., Sinz M., Skerjanec A. In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America Perspective. Drug Metab. Dispos. 2009, 37:1339-1354.
4. Court M.H., Duan S.X., Hesse L.M., Venkatakrishnan K., Greenblatt D.J. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001, 94:110-119.
5. Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 2002, 3:561-597.
6. Dong B., Qatanani M., Moore D.D. Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 2009, 50:622-629.
7. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182:1223-1230.
8. Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 1999, 56:1329-1339.
9. Guo G.L., Lambert G., Negishi M., Ward J.M., Brewer H.B., Kliewer S.A., Gonzalez F.J., Sinal C.J. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 2003, 278:45062-45071.
10. Haas M., Kletzmayer J., Staudinger T., Bohmig G., Mayer G., Leko-Mohr Z., Druml W. Hypothyroidism as a cause of tacrolimus intoxication and acute renal failure: a case report. Wien. Klin. Wochenschr. 2000, 112:939-941.
11. Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 2001, 29:1480-1484.
12. Honkakoski P., Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 2000, 347:321-337.
13. Istrate M.A., Nussler A.K., Eichelbaum M., Burk O. Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding. Biochem. Biophys. Res. Commun. 2010, 393:688-693.
14. Kang P., Liao M., Wester M.R., Leeder J.S., Pearce R.E., Correia M.A. CYP3A4-mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab. Dispos. 2008, 36:490-499.
15. Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J., Levy R.H. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 1994, 47:1969-1979.
16. Kliewer S.A., Lehmann J.M., Willson T.M. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999, 284:757-760.
17. Lahtela J.T., Arranto A.J., Sotaniemi E.A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 1985, 34:911-916.
18. Liddle C., Goodwin B.J., George J., Tapner M., Farrell G.C. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J. Clin. Endocrinol. Metab. 1998, 83:2411-2416.
19. Maglich J.M., Watson J., McMillen P.J., Goodwin B., Willson T.M., Moore J.T. The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J. Biol. Chem. 2004, 279:19832-19838.
20. Mizuno Y., Kanou Y., Rogatcheva M., Imai T., Refetoff S., Seo H., Murata Y. Genomic organization of mouse ZAKI-4 gene that encodes ZAKI-4 alpha and beta isoforms, endogenous calcineurin inhibitors, and changes in the expression of these isoforms by thyroid hormone in adult mouse brain and heart. Eur. J. Endocrinol. 2004, 150:371-380.
21. O'Leary K.A., Li H.C., Ram P.A., McQuiddy P., Waxman D.J., Kasper C.B. Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5'-flank of the oxidoreductase gene. Mol. Pharmacol. 1997, 52:46-53.
22. Omura K., Kiyosawa N., Uehara T., Hirode M., Shimizu T., Miyagishima T., Ono A., Nagao T., Urushidani T. Gene expression profiling of rat liver treated with serum triglyceride-decreasing compounds. J. Toxicol. Sci. 2007, 32:387-399.
23. Ooe H., Kon J., Oshima H., Mitaka T. Thyroid hormone is necessary for expression of constitutive androstane receptor in rat hepatocytes. Drug Metab. Dispos. 2009, 37:1963-1969.
24. Oscarson M., Zanger U.M., Rifki O.F., Klein K., Eichelbaum M., Meyer U.A. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 2006, 80:440-456.
25. Pearce R.E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 2002, 30:1170-1179.
26. Qatanani M., Zhang J., Moore D.D. Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 2005, 146:995-1002.
27. Ram P.A., Waxman D.J. Hepatic P450 expression in hypothyroid rats: differential responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid hormone. Mol. Endocrinol. 1991, 5:13-20.
28. Rosenberg D.W., Drummond G.S., Smith T.J. Depletion of cytochrome P-450 by thyroid hormone and cobalt-protoporphyrin IX in rat liver: evidence that susceptibility varies among forms of the heme protein. Pharmacology 1995, 51:254-262.
29. Roy P., Tretyakov O., Wright J., Waxman D.J. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab. Dispos. 1999, 27:1309-1318.
30. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., Liu Y., Klaassen C.D., Brown K.K., Reinhard J., Willson T.M., Koller B.H., Kliewer S.A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3369-3374.
31. Surks M.I., Sievert R. Drugs and thyroid function. N. Engl. J. Med. 1995, 333:1688-1694.
32. Webb S.J., Xiao G.H., Geoghegan T.E., Prough R.A. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone. Mol. Pharmacol. 1996, 49:276-287.
33. Wei P., Zhang J., Egan-Hafley M., Liang S., Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000, 407:920-923.
34. Wei P., Zhang J., Dohan D., Han Y., Moore D.D. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J. 2002, 2:117-126.
35. Willson T.M., Kliewer S.A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 2002, 1:259-266.
36. Wu Y., Koenig R.J. Gene regulation by thyroid hormone. Trends Endocrinol. Metab. 2000, 11:207-211.
37. Xie W., Evans R.M. Orphan nuclear receptors: the exotics of xenobiotics. J. Biol. Chem. 2001, 276:37739-37742.
38. Xie W., Barwick J.L., Simon C.M., Pierce A.M., Safe S., Blumberg B., Guzelian P.S., Evans R.M. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 2000, 14:3014-3023.
39. Zhang J., Huang W., Qatanani M., Evans R.M., Moore D.D. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 2004, 279:49517-49522.